JP2017531687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017531687A5 JP2017531687A5 JP2017522502A JP2017522502A JP2017531687A5 JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5 JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017522502 A JP2017522502 A JP 2017522502A JP 2017531687 A5 JP2017531687 A5 JP 2017531687A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- modified human
- modified
- immune system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 123
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 119
- 238000000034 method Methods 0.000 claims description 78
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 65
- 210000000987 immune system Anatomy 0.000 claims description 60
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 claims description 51
- 102000044493 human CDCA4 Human genes 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 37
- 102000025171 antigen binding proteins Human genes 0.000 claims description 27
- 108091000831 antigen binding proteins Proteins 0.000 claims description 27
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 25
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 25
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 25
- 239000012636 effector Substances 0.000 claims description 23
- 230000003834 intracellular effect Effects 0.000 claims description 21
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- -1 CD79b Proteins 0.000 claims description 18
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 16
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 16
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 16
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 102100027207 CD27 antigen Human genes 0.000 claims description 13
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 12
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 230000002209 hydrophobic effect Effects 0.000 claims description 12
- 238000009169 immunotherapy Methods 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 11
- 102100027271 40S ribosomal protein SA Human genes 0.000 claims description 8
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 239000013603 viral vector Substances 0.000 claims description 8
- 230000001400 myeloablative effect Effects 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000003463 hyperproliferative effect Effects 0.000 claims description 5
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 4
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 4
- 102100035893 CD151 antigen Human genes 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 4
- 108010065524 CD52 Antigen Proteins 0.000 claims description 4
- 102100027221 CD81 antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 4
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 4
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 4
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 4
- 101710181403 Frizzled Proteins 0.000 claims description 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 4
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 4
- 102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 claims description 4
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 4
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 4
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 4
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 4
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 4
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 4
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 claims description 4
- 101000997535 Homo sapiens Growth hormone-releasing hormone receptor Proteins 0.000 claims description 4
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 4
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 4
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 4
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 4
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 4
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 4
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 4
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 4
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 4
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 4
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims description 4
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 102100023123 Mucin-16 Human genes 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims description 4
- 108010065129 Patched-1 Receptor Proteins 0.000 claims description 4
- 108010071083 Patched-2 Receptor Proteins 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 102100028680 Protein patched homolog 1 Human genes 0.000 claims description 4
- 102100036894 Protein patched homolog 2 Human genes 0.000 claims description 4
- 101150097792 Robo1 gene Proteins 0.000 claims description 4
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 4
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 4
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 4
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 4
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims description 4
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 4
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 4
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims description 4
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 4
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 4
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims description 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 102000003425 Tyrosinase Human genes 0.000 claims description 4
- 108060008724 Tyrosinase Proteins 0.000 claims description 4
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 4
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 4
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 2
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010066476 Haematological malignancy Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 2
- 231100000782 microtubule inhibitor Toxicity 0.000 claims description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 2
- 229960000951 mycophenolic acid Drugs 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000002918 testicular germ cell tumor Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 claims 4
- 101100364669 Caenorhabditis elegans lin-18 gene Proteins 0.000 claims 4
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims 4
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims 4
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 4
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 claims 4
- 101100364671 Mus musculus Ryk gene Proteins 0.000 claims 4
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 claims 4
- 102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 claims 4
- 102100025247 Neurogenic locus notch homolog protein 3 Human genes 0.000 claims 4
- 102100025254 Neurogenic locus notch homolog protein 4 Human genes 0.000 claims 4
- 108010029755 Notch1 Receptor Proteins 0.000 claims 4
- 108010029751 Notch2 Receptor Proteins 0.000 claims 4
- 108010029756 Notch3 Receptor Proteins 0.000 claims 4
- 108010029741 Notch4 Receptor Proteins 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 2
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 2
- 101150028321 Lck gene Proteins 0.000 claims 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 210000003515 double negative t cell Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 description 2
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462069168P | 2014-10-27 | 2014-10-27 | |
| US62/069,168 | 2014-10-27 | ||
| PCT/US2015/057652 WO2016069647A1 (en) | 2014-10-27 | 2015-10-27 | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017531687A JP2017531687A (ja) | 2017-10-26 |
| JP2017531687A5 true JP2017531687A5 (enExample) | 2018-12-06 |
| JP7005346B2 JP7005346B2 (ja) | 2022-02-04 |
Family
ID=54545485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522502A Active JP7005346B2 (ja) | 2014-10-27 | 2015-10-27 | 養子細胞免疫療法の有効性を増強させるための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10828352B2 (enExample) |
| EP (1) | EP3212223B1 (enExample) |
| JP (1) | JP7005346B2 (enExample) |
| KR (1) | KR102357004B1 (enExample) |
| CN (1) | CN107106611B (enExample) |
| AU (1) | AU2015339402B2 (enExample) |
| BR (2) | BR122021000068A8 (enExample) |
| CA (1) | CA2965347C (enExample) |
| ES (1) | ES2897731T3 (enExample) |
| HK (1) | HK1243631A1 (enExample) |
| MX (1) | MX389823B (enExample) |
| NZ (1) | NZ731279A (enExample) |
| RU (1) | RU2716716C2 (enExample) |
| WO (1) | WO2016069647A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| WO2013151771A1 (en) | 2012-04-05 | 2013-10-10 | Massachusetts Institute Of Technology | Immunostimulatory compositions and methods of use thereof |
| JP2017515464A (ja) | 2014-04-10 | 2017-06-15 | シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート | 細胞免疫療法のための方法および組成物 |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| CA2991690A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory t cells and use of same in immunotherapy |
| KR20180033537A (ko) | 2015-07-21 | 2018-04-03 | 더 칠드런스 메디칼 센터 코포레이션 | Pd-l1 발현 조혈 줄기 세포 및 용도 |
| AU2016306209B2 (en) | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
| HK1254836A1 (zh) | 2015-10-30 | 2019-07-26 | Nbe-Therapeutics Ag | 抗-ror1抗体 |
| CN108848669B (zh) | 2016-01-20 | 2022-06-07 | 斯克利普斯研究所 | Ror1抗体组合物和相关方法 |
| EP4006056A1 (en) | 2016-02-02 | 2022-06-01 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| CA3022267A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| US10688104B2 (en) * | 2016-05-20 | 2020-06-23 | Eli Lilly And Company | Combination therapy with Notch and PD-1 or PD-L1 inhibitors |
| CN106199005B (zh) * | 2016-07-26 | 2019-02-01 | 浙江大学 | 采用cd137表达量检测淋巴细胞抗大肠癌活性的方法 |
| RU2019120398A (ru) | 2016-12-03 | 2021-01-12 | Джуно Терапьютикс, Инк. | Способы определения дозировки cart-клеток |
| BR112019011207A2 (pt) | 2016-12-05 | 2019-10-08 | Juno Therapeutics Inc | produção de células modificadas para terapia celular adotiva |
| WO2018134824A1 (en) * | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
| CN107267555B (zh) * | 2017-05-27 | 2020-03-20 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 |
| WO2019030223A1 (en) | 2017-08-07 | 2019-02-14 | Nbe-Therapeutics Ag | ANTHRACYCLINE ANTIBODY-MEDICINAL CONJUGATES HAVING HIGH IN VIVO TOLERABILITY |
| US12398191B2 (en) | 2017-08-11 | 2025-08-26 | Fred Hutchinson Cancer Center | BRAF-specific TCRs and uses thereof |
| JP7654240B2 (ja) * | 2017-09-19 | 2025-04-01 | マサチューセッツ インスティテュート オブ テクノロジー | キメラ抗原受容体ｔ細胞治療のための組成物およびその使用 |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| KR20200070236A (ko) * | 2017-09-26 | 2020-06-17 | 롱우드 유니버시티 | 면역치료제로서의 pd1-특이적 키메라 항원 수용체 |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| US20200209240A1 (en) * | 2017-11-20 | 2020-07-02 | Julius-Maximilians-Universität Würzburg | Cd19cart cells eliminate myeloma cells that express very low levels of cd19 |
| EP3716980A1 (en) | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| CN109810995B (zh) | 2017-12-06 | 2020-10-02 | 阿思科力(苏州)生物科技有限公司 | 编码car的核苷酸序列、表达该car的robo1 car-nk细胞及其制备和应用 |
| CN108148137B (zh) * | 2017-12-29 | 2021-03-23 | 中国人民解放军第四军医大学 | 一种b7h4/1e10单克隆抗体及其应用 |
| BR112021003830A2 (pt) * | 2018-08-28 | 2021-07-20 | Fred Hutchinson Cancer Research Center | métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida |
| CN111544585B (zh) * | 2019-02-11 | 2024-12-27 | 北京卡替医疗技术有限公司 | 一种可助推免疫细胞在体内扩增的佐剂 |
| EP3941511A2 (en) | 2019-03-20 | 2022-01-26 | Massachusetts Institute of Technology | Uses of amphiphiles in immune cell therapy and compositions therefor |
| EP3983539A1 (en) * | 2019-06-14 | 2022-04-20 | Flagship Pioneering Innovations VI, LLC | Circular rnas for cellular therapy |
| WO2021129927A1 (en) * | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2021263211A2 (en) * | 2020-06-25 | 2021-12-30 | Houston Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| US20050129671A1 (en) * | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| US20090324630A1 (en) * | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| SG10201602253SA (en) | 2011-03-23 | 2016-05-30 | Hutchinson Fred Cancer Res | Method and compositions for cellular immunotherapy |
| WO2012140130A1 (en) * | 2011-04-13 | 2012-10-18 | Immunicum Ab | Method for proliferation of antigen-specific t cells |
| JP6117515B2 (ja) * | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | 髄膜腫治療用医薬組成物 |
| LT2961831T (lt) * | 2013-02-26 | 2020-11-10 | Memorial Sloan Kettering Cancer Center | Kompozicijos ir būdai, skirti imunoterapijai |
| TWI654206B (zh) * | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| ES2831315T3 (es) * | 2013-04-03 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | Generación efectiva de células T dirigidas al tumor derivadas de células madre pluripotentes |
-
2015
- 2015-10-27 JP JP2017522502A patent/JP7005346B2/ja active Active
- 2015-10-27 CN CN201580071144.9A patent/CN107106611B/zh active Active
- 2015-10-27 AU AU2015339402A patent/AU2015339402B2/en active Active
- 2015-10-27 US US15/521,794 patent/US10828352B2/en active Active
- 2015-10-27 BR BR122021000068A patent/BR122021000068A8/pt not_active Application Discontinuation
- 2015-10-27 RU RU2017114174A patent/RU2716716C2/ru active
- 2015-10-27 MX MX2017005344A patent/MX389823B/es unknown
- 2015-10-27 WO PCT/US2015/057652 patent/WO2016069647A1/en not_active Ceased
- 2015-10-27 BR BR112017008710A patent/BR112017008710A8/pt not_active Application Discontinuation
- 2015-10-27 NZ NZ731279A patent/NZ731279A/en unknown
- 2015-10-27 HK HK18103005.7A patent/HK1243631A1/zh unknown
- 2015-10-27 ES ES15795073T patent/ES2897731T3/es active Active
- 2015-10-27 CA CA2965347A patent/CA2965347C/en active Active
- 2015-10-27 KR KR1020177013868A patent/KR102357004B1/ko active Active
- 2015-10-27 EP EP15795073.4A patent/EP3212223B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017531687A5 (enExample) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| Johdi et al. | Colorectal cancer immunotherapy: options and strategies | |
| Baxevanis et al. | Cancer immunotherapy | |
| Kiesgen et al. | Chimeric antigen receptor (CAR) T-cell therapy for thoracic malignancies | |
| JP7487112B2 (ja) | Ｃｄ１９指向性キメラ抗原受容体および免疫療法におけるその使用 | |
| Kershaw et al. | Gene-engineered T cells for cancer therapy | |
| Wang et al. | Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| Spear et al. | Strategies to genetically engineer T cells for cancer immunotherapy | |
| JP2022535429A (ja) | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ | |
| JP2020509767A5 (enExample) | ||
| JP7717686B2 (ja) | キメラｃｄ３融合タンパク質と抗ｃｄ３ベースの二重特異性ｔ細胞活性化エレメントの複合発現 | |
| CN111787938A (zh) | 靶向bcma的嵌合抗原受体、靶向cd19的嵌合抗原受体及组合疗法 | |
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| JP2015527070A5 (enExample) | ||
| CN111247241A (zh) | T细胞受体缺陷型嵌合抗原受体t细胞和其使用方法 | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| CN108410892A (zh) | 降低由pd-l1诱导的免疫耐受性 | |
| JPWO2019157454A5 (enExample) | ||
| WO2018210279A1 (zh) | Toll样受体激动剂与免疫效应细胞的联用 | |
| Danhof et al. | CARs and other T cell therapies for MM: the clinical experience |